# Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

> **NCT04698213** · PHASE2 · UNKNOWN · sponsor: **Consorzio Oncotech** · enrollment: 75 (estimated)

## Conditions studied

- Renal Carcinoma Metastatic

## Interventions

- **DRUG:** Axitinib Oral Tablet
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04698213
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-07
- **Primary completion:** 2023-09
- **Final completion:** 2024-10
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2021-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04698213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04698213, "Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04698213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*